Cargando…

Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab

We report a patient with macular oedema due to type 1 macular telangiectasia responding to intravitreal aflibercept injection. A 51-year-old man was diagnosed with type 1 idiopathic macular telangiectasia (IMT) in the right eye. The macular oedema was refractory to initial treatment with intravitrea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shibeeb, O'Sam, Vaze, Anagha, Gillies, Mark, Gray, Timothy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198777/ https://www.ncbi.nlm.nih.gov/pubmed/25349755 http://dx.doi.org/10.1155/2014/219792

Ejemplares similares

Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex)
por: Loutfi, Mohamed, et al.
Publicado: (2014)

Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia
por: Aydoğan, Tuğba, et al.
Publicado: (2016)

Aflibercept monotherapy versus aflibercept with targeted retinal laser to peripheral retinal ischemia for diabetic macular oedema (LADAMO)
por: Cornish, E. E., et al.
Publicado: (2023)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

Management of Idiopathic Macular Telangiectasia Type 2
por: Khodabande, Alireza, et al.
Publicado: (2019)

Idiopathic Macular Telangiectasia Type 1 with Ruptured Retinal Arterial Macroaneurysm Post Intravitreal Bevacizumab
por: Nakhwa, Chinmay P., et al.
Publicado: (2015)

Intravitreal aflibercept for treatment of macular oedema associated with immune recovery uveitis
por: Rothova, Aniki, et al.
Publicado: (2020)

EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE
por: Kowalczuk, Laura, et al.
Publicado: (2017)

Unusual Presentation of Type 1 Idiopathic Macular Telangiectasia
por: Bentaleb Machkour, Zaïnab, et al.
Publicado: (2017)

Intravitreal Bevacizumab for Choroidal Neovascular Membrane in Macular Telangiectasia Type 2
por: Gonzalez Martinez, Orlando G, et al.
Publicado: (2023)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Type 1 Idiopathic Macular Telangiectasia Associated with Type 3 Neovascularization
por: Tilleul, Julien, et al.
Publicado: (2014)

Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia
por: Rishi, Pukhraj, et al.
Publicado: (2009)

HbA1c as a predictor for response of bevacizumab in diabetic macular oedema
por: Sharma, Sadhana, et al.
Publicado: (2020)

12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
por: Niedzwiecki, Mateusz, et al.
Publicado: (2021)

IMPAIRMENTS IN CONE PIGMENT REGENERATION AND ABSOLUTE THRESHOLD IN MACULAR TELANGIECTASIA TYPE 2
por: Simunovic, Matthew P., et al.
Publicado: (2022)

Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
por: McCloskey, Clare F., et al.
Publicado: (2018)

Retinal arteriolar oxygen saturation predicts the need for intravitreal aflibercept in patients with diabetic macular oedema
por: Blindbæk, Søren Leer, et al.
Publicado: (2020)

Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema
por: Kim, Yu Cheol, et al.
Publicado: (2020)

Analysis of candidate genes for macular telangiectasia type 2
por: Parmalee, Nancy L., et al.
Publicado: (2010)

When is macular edema not macular edema? An update on macular telangiectasia type 2
por: Wu, Lihteh
Publicado: (2015)

Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2
por: Behrens, Alice, et al.
Publicado: (2018)

Demographic Features of Idiopathic Macular Telangiectasia in Korean Patients
por: Kim, Sung Hyun, et al.
Publicado: (2015)

A complete clinical review of idiopathic macular telangiectasia
por: Jayasri, P., et al.
Publicado: (2023)

Ultrastructural and clinical evidence of subretinal debris accumulation in type 2 macular telangiectasia
por: Cherepanoff, Svetlana, et al.
Publicado: (2012)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders
por: Salimi, Ali, et al.
Publicado: (2021)

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
por: Lee, Junyeop, et al.
Publicado: (2022)

Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa
por: Strong, Stacey A, et al.
Publicado: (2020)

Translating evidence into practice: recommendations by a UK expert panel on the use of aflibercept in diabetic macular oedema
por: Pearce, Ian, et al.
Publicado: (2019)

Identification of a Potential Susceptibility Locus for Macular Telangiectasia Type 2
por: Parmalee, Nancy L., et al.
Publicado: (2012)

Preretinal hemorrhage as a presenting sign of idiopathic macular telangiectasia type 2
por: Osher, James M, et al.
Publicado: (2015)

Suspected Neratinib Macular Toxicity Presenting As Macular Telangiectasia Type II
por: Enghelberg, Moises, et al.
Publicado: (2023)

Reduced foveal cone density in early idiopathic macular telangiectasia
por: Song, Hongxin, et al.
Publicado: (2021)

Ziv-aflibercept in macular disease
por: Mansour, Ahmad M, et al.
Publicado: (2015)

The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab
por: Unsal, Erkan, et al.
Publicado: (2018)

One-year results of switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab
por: Abouhussein, Mahmoud Alaa, et al.
Publicado: (2021)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa, Bernardete, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3kaa1lqb2n69uoc25c601g57eg